Skip to main content
. 2022 Sep 15;13:1007326. doi: 10.3389/fimmu.2022.1007326

Figure 4.

Figure 4

Validation in GSE cohort. (A) TIDE analysis was performed in the combined GSE cohort; (B) In the GEO cohort, Cluster2 also had a higher TIDE score; (C, D) The proportion of immunotherapy responders and non-responders in Cluster1 and Cluster2 patients; (E) KM survival curve of Cluster1 and Cluster2 patients; (F–H) Clinical differences between Cluster1 and Cluster2 (gender, age and grade). * = P < 0.05.